support

# Expert Assessment: ALOX15-Driven Ferroptosis in AD Oligodendrocytes

## Executive Summary

This hypothesis presents a mechanistically plausible pathway connecting ALOX15 enzymatic activity to oligodendrocyte death via ferroptosis in Alzheimer's Disease. The target has favorable druggability characteristics and a history of drug discovery efforts, though significant translational challenges exist, particularly regarding human relevance in AD and safety liabilities from eicosanoid pathway modulation.

**Confidence Score: 0.62** (revised downward from 0.82 given translational context)

---

## 1. Druggability Assessment

### Target Characteristics
| Property | Assessment | Notes |
|----------|------------|-------|
| Enzyme class | Non-heme iron dioxygenase | Well-characterized structure; ~75 kDa cytosolic protein |
| Active site | Druggable | Iron-centered active site; confirmed crystallographic data |
| Binding pockets | Defined | Multiple structural features amenable to small molecule engagement |
| Previous attempts | Extensive | Investigated for asthma, MS, cardiovascular disease, oncology |

**Verdict**: ALOX15 is a druggable target with established medicinal chemistry precedent. The active site iron creates both opportunities (high-affinity chelation-based inhibitors) and challenges (specificity across lipoxygenase family).

---

## 2. Tool Compounds Assessment

### Existing Research Tools

| Compound | Specificity | Limitation |
|----------|-------------|------------|
| **PD146176 (BL-0007)** | Selective for ALOX15 | Developed for EAE/MS; limited